Advaxis Presents Preliminary Data From a Phase 1/2 Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combination With Chemoradiation Showing Complete Response and No Recurrences to Date in All Treated Patients

Data Highlighted in Oral Presentation at the International Anal Neoplasia Society Scientific Meeting 2015

PRINCETON, N.J., March 16, 2015 -- Advaxis, Inc. (ADXS), a clinical-stage cancer immunotherapy company, presented preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in 10 patients with HPV-associated locally advanced anal cancer indicating that all patients who have completed treatment in the study have had a complete response with no evidence of recurrence to date (follow-up ranging from 0.5 -- 24 months). The preliminary data also show that the investigational immunotherapy was well tolerated by the treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which include chills/rigors, fever and nausea.

Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases

PLYMOUTH MEETING, Pa., March 16, 2015 -- Inovio Pharmaceuticals, Inc. (INO) announced today that the company and its academic collaborators, including the University of Pennsylvania (UPenn), were awarded a new five-year $16 million Integrated Preclinical/Clinical AIDS Vaccine Development Program grant from the National Institute of Allergy and Infectious Diseases (NIAID).

This five-year program grant was awarded based on the clinical successes of Inovio's PENNVAX^(R) HIV vaccine program. The grant will fund research to expand PENNVAX coverage of HIV strains as well as to further enhance antibody responses generated by the vaccine.

Repligen Reports Financial Results for the Year 2014 and Issues 2015 Financial Guidance

- Year 2014 Product Sales Increase 27% to a Record $60.4 Million -
- Fourth Quarter Product Sales Increase 49% to $15.4 Million -
- Conference Call and Webcast Today at 8:30 a.m. EDT -

WALTHAM, Mass., March 13, 2015 -- Repligen Corporation (RGEN) today reported financial results for the fourth quarter and year ended December 31, 2014. Below are the Company's performance highlights for these periods, followed by financial guidance for the year 2015 and access information for today's webcast and conference call.

T-Bird Pharma Inc. Announces Partnership with Medna Biosciences Inc.

VICTORIA, March 11, 2015 - T-Bird Pharma Inc. (TSXV:TPI.V - News) ("T-Bird" or the "Company"), a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP") to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR"), is pleased to announce that it, together with certain of its shareholders, has entered into an agreement with Medna Biosciences Inc. ("Medna") whereby Medna will acquire (the "Escrow Transfer") a total of 20,156,790 common shares of T-Bird (45% of the Company's issued shares) from five of its founding shareholders, including its former CEO and CFO, at a price of $0.21 per share. This block of shares is currently held in escrow and the shares will be transferred within escrow and remain bound by those terms and conditions. The Escrow Transfer is subject to TSX-V approval.